Abstract

Background

Patients receiving surgical treatment of acute type A Aortic Dissection (aTAAD) are common to suffer organ dysfunction in the intensive care unit due to overwhelming inflammation. Previous studies have revealed that glucocorticoids may reduce complications in certain patient groups, but evidence between postoperative glucocorticoids administration and improvement in organ dysfunction after aTAAD surgery are lacking.

Methods

This study will be an investigator-initiated, prospective, single-blind, randomized, single-center study. Subjects with confirmed diagnosis of aTAAD undergoing surgical treatment will be enrolled and 1:1 randomly assigned to receive either glucocorticoids or normal treatment. All patients in the glucocorticoids group will be given methylprednisolone intravenously for 3 days after enrollment. The primary endpoint will be the amplitude of variation of Sequential Organ Failure Assessment score on post-operative day 4 compared to baseline.

Discussion

The trial will explore the rationale for postoperative application of glucocorticoids in patients after aTAAD surgery.

Trial registration

This study has been registered on ClinicalTrials.gov (NCT04734418).

Details

Title
Postoperative glucocorticoids in patients with acute type A aortic dissection (GLAD): study protocol for a prospective, single-center, randomized controlled trial
Author
Yi-zhi Deng; Ming-hao, Luo; Jing-chao, Luo; Jia-kun, Li; Jia-qi, Chen; Yi-jie, Zhang; Jun-yi, Hou; Su, Ying; Guo-wei, Tu; Luo, Zhe
Pages
1-8
Section
Study Protocol
Publication year
2023
Publication date
2023
Publisher
BioMed Central
e-ISSN
14712253
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2815590520
Copyright
© 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.